Dr. Alvira Macanovic reports

VENTRIPOINT UNVEILS NEW INTEGRATED PRODUCT WITH ASCEND CARDIOVASCULAR

Ventripoint Diagnostics Ltd. and Ascend Cardiovascular LLC have developed a new integrated product. Today's announcement marks a significant milestone in Ventripoint's commitment to the collaboration between the two companies. Ascend fits perfectly into Ventripoint's road map for innovation and is a key step in the company's mission to improve patient lives and become the standard of care.

Ascend is seamlessly integrated with leading EHRs (electronic health records) and imaging systems. Its existing technology has been installed at more than 1,000 top-ranked health care facilities and more than 600 health systems with approximately 50,000 users across the United States.

Ventripoint has successfully and seamlessly integrated its specialized AI-powered (artificial intelligence) 3-D Echo software application with Ascend's diagnostic viewer, InView, and reporting application, Cardiovascular Structured Reporting. This cardiovascular workflow product provides an end-to-end solution that rivals other products on the market. It is streamlined, smart and effective for cardiology reading, reporting and diagnostics, thereby improving diagnosis and monitoring of fetal, pediatric and adult congenital heart disease.

"We are excited to embark on this collaborative journey with Ascend Cardiovascular," stated Dr. Alvira Macanovic, president and chief executive officer of Ventripoint Diagnostics. "We see this collaboration evolving progressively in its possibilities. We believe that, by integrating Ventripoint's technology in diagnostic medical imaging with Ascend's expertise in cardiology IT, this will be a successful integrated product. The product will offer a seamless and comprehensive approach to diagnosing and treating cardiovascular conditions."

After months of development, Ventripoint stands ready to successfully unveil this integrated product with its newest partner at the eighth World Congress of Pediatric Cardiology and Cardiac Surgery in Washington, D.C., later this month.

"This is an important milestone and validation of Ascend's commitment to providers caring for children with heart disease. We are excited to enable the routine, efficient use of Ventripoint's advanced 3-D image analysis in pediatric cardiology," stated Dr. Jeff Soble, chief executive officer of Ascend.

As the collaboration between Ventripoint and Ascend continues to evolve, both companies remain committed to driving innovation and excellence in cardiovascular health technology. This integrated product marks an exciting milestone in the advancement of cardiac care and solving today's and anticipating tomorrow's challenges.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI (magnetic resonance imaging). This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.